The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) reviewed, on 23 October, early data from clinical studies for the three authorised H1N1 flu pandemic vaccines, Celvapan, Focetria and Pandemrix. The committee concluded to maintain the recommendation it adopted in September, namely that the three vaccines be preferably given as two doses, at least three weeks apart. The data currently available for Pandemrix and for Focetria indicate that one dose may be sufficient in adults, but are too limited to allow the committee to recommend the general use of a single-dose vaccination schedule. The European Commission and the member states had said that they expected that the CHMP would recommend only one dose for all vaccines, during the extraordinary Health Council in Luxembourg, on 12 October. This decision might have an impact on the distribution of the vaccines, in particular on the eventual reselling to countries that did not have any vaccines yet and to countries outside the European Union.